For the quarter ending 2025-09-30, SKYE made $13,774,408 in revenue. -$12,754,660 in net income. Net profit margin of -92.60%.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 9,357,444 | 14,337,753 | ||
| General and administrative | 3,907,090 | 3,906,172 | ||
| Change in estimate for legal contingency | 0 | - | ||
| Total operating expenses | 13,264,534 | 18,243,925 | ||
| Operating loss | -13,264,534 | -18,243,925 | ||
| Interest (income) expense | 0 | 0 | ||
| Interest and other income, net | 418,474 | 533,090 | ||
| Gains from asset sales | 91,400 | 89,363 | ||
| Other expense | 0 | 0 | ||
| Total other (income) expense, net | 509,874 | 622,453 | ||
| Loss before income taxes | -12,754,660 | -17,621,472 | ||
| Provision for income taxes | 0 | 3,400 | ||
| Net loss | -12,754,660 | -17,624,872 | ||
| Basic (in dollars per share) | -0.32 | -0.44 | ||
| Basic (in shares) | 39,665,927 | 39,659,266 | ||
| Diluted (in dollars per share) | -0.32 | -0.44 | ||
| Diluted (in shares) | 39,665,927 | 39,659,266 | ||
Skye Bioscience, Inc. (SKYE)
Skye Bioscience, Inc. (SKYE)